LK-4細(xì)胞
是否是腫瘤細(xì)胞： 0
物種來(lái)源： 小鼠
ATCC Number： CRL-2345?
生長(zhǎng)狀態(tài)： 懸浮生長(zhǎng)
運(yùn)輸方式： 凍存運(yùn)輸
數(shù)量： 大量
細(xì)胞形態(tài)： **樣
**類型： IgG1; kappa light chain
Designations: LK-4
Depositors: S Karpatkin
LK-4細(xì)胞Isotype: IgG1; kappa light chain
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology: lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products: immunoglobulin; monoclonal antibody; against human platelet glycoprotein GPIIIa.
Permits/Forms: LK-4細(xì)胞In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments: The hybridoma cell line LK-4 secretes a mouse monoclonal antibody (IgG1k) that recognizes human platelet glycoprotein GPIIIa.
The antibody can differentiate platelet PLA1/PLA1, PLA1/PLA2 and PLA2/PLA2 genotypes on soluble platelet extracts; it can recognize but not differentiate intact platelets. [38656]
The antibody inhibits binding of human anti- PLA1 antibody to human platelets.
The antibody is useful in immunoblot and ELISA assays.
The line was produced by fusing P3U1 mouse myeloma cells with spleen cells from a BALB/c female mouse differentially immunized with human PLA2 platelets and cyclophosphamide, followed by PLA1 platelets. [38657]
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. LK-4細(xì)胞To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 38656: Liu LX, et al. A monoclonal antibody (LK-4) which differentiates PLA1 from PLA2 platelet extracts but not intact platelets. Thromb. Res. 66: 309-320, 1992. PubMed: 1384161
38657: Liu LX, et al. Development of a monoclonal antibody capable of differentiating platelet PLA1/PLA1, PLA1/PLA2 and PLA2/PLA2 genotypes. Br. J. Haematol. 81: 113-117, 1992. PubMed: 1520609
38658: Liu LX, et al. Heterogenous inhibition of platelet aggregation by monoclonal antibodies binding to multiple sites on GPIIIa. Br. J. Haematol. 91: 976-982, 1995. PubMed: 8547151
38660: Valetin N, et al. LK-4細(xì)胞Involvement of the cysteine-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: evidence for heterogeneity in the humoral response. Blood 85: 3028-3033, 1995. PubMed: 7756638
38661: Liu LX, et al. Inhibition of binding of anti-PLA1 antibodies to platelets with monoclonal antibody LK-4. Evidence for multiple PLA1 receptor sites on platelet GPIIIa. Blood 88: 3601-3607, 1996. PubMed: 8896429
